Back to top
more

Astellas Pharma (ALPMY)

(Delayed Data from OTC)

$9.55 USD

9.55
452,047

+0.01 (0.10%)

Updated Apr 26, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ALPMY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Astellas Pharma Inc falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents -99,999 2,982 2,765 2,988 3,008
Receivables NA 3,352 3,312 3,218 3,400
Notes Receivable NA 0 0 0 0
Inventories NA 1,311 1,255 1,478 1,385
Other Current Assets NA 250 238 177 166
Total Current Assets NA 7,894 7,568 7,861 7,959
Net Property & Equipment NA 2,154 2,205 2,384 2,464
Investments & Advances NA 831 835 928 724
Other Non-Current Assets NA 182 244 306 312
Deferred Charges NA 633 593 488 485
Intangibles NA 6,698 7,594 8,428 9,229
Deposits & Other Assets NA 77 78 89 93
Total Assets NA 18,470 19,118 20,483 21,268
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 1,054 1,072 1,124 1,578
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 1,354 1,516 1,335 3,172
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 39 265 76 37
Other Current Liabilities NA 3,011 2,782 2,802 2,542
Total Current Liabilities NA 5,459 5,635 5,337 7,328
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 45 48 164 254
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1,628 1,467 2,495 1,859
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 7,132 7,148 7,996 9,440
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 774 844 928 945
Capital Surplus NA 1,363 1,471 1,602 1,628
Retained Earnings NA 6,828 7,740 8,588 8,311
Other Equity NA 2,561 2,029 1,508 1,009
Treasury Stock NA 189 114 139 66
Total Shareholder's Equity NA 11,338 11,970 12,488 11,827
Total Liabilities & Shareholder's Equity NA 18,470 19,118 20,483 21,268
Total Common Equity 0 11,338 11,970 12,488 11,827
Shares Outstanding 1,809.60 1,809.60 1,835.80 1,861.70 1,888.80
Book Value Per Share 0.00 6.27 6.52 6.71 6.26

Fiscal Year End for Astellas Pharma Inc falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 1,941 2,509 4,401 2,982
Receivables NA 3,440 3,482 3,484 3,352
Notes Receivable NA NA NA 0 0
Inventories NA 1,537 1,474 1,462 1,311
Other Current Assets NA 223 241 272 250
Total Current Assets NA 7,141 7,706 9,617 7,894
Net Property & Equipment NA 1,965 2,046 2,123 2,154
Investments & Advances NA 797 819 807 831
Other Non-Current Assets NA 142 150 168 182
Deferred Charges NA 290 306 735 633
Intangibles NA 12,514 13,361 6,907 6,698
Deposits & Other Assets NA 58 60 70 77
Total Assets NA 22,907 24,447 20,425 18,470
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA 0 0
Accounts Payable NA 1,023 1,016 1,011 1,054
Current Portion Long-Term Debt NA 2,769 2,874 2,256 0
Current Portion Capital Leases NA 684 681 730 1,354
Accrued Expenses NA NA NA 0 0
Income Taxes Payable NA 237 216 119 39
Other Current Liabilities NA 3,132 3,232 3,123 3,011
Total Current Liabilities NA 7,845 8,020 7,238 5,459
Mortgages NA NA NA 0 0
Deferred Taxes/Income NA 476 639 48 45
Convertible Debt NA NA NA 0 0
Long-Term Debt NA 3,154 3,264 365 0
Non-Current Capital Leases NA NA NA 0 0
Other Non-Current Liabilities NA 1,212 1,252 1,628
Minority Interest (Liabilities) NA NA NA 0 0
Total Liabilities NA 12,685 13,135 8,903 7,132
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA 0 0
Common Stock (Par) NA 700 711 752 774
Capital Surplus NA 1,244 1,257 1,319 1,363
Retained Earnings NA 5,703 6,103 6,457 6,828
Other Equity NA 2,807 3,478 3,246 2,561
Treasury Stock NA 232 237 252 189
Total Shareholder's Equity NA 10,222 11,311 11,522 11,338
Total Liabilities & Shareholder's Equity NA 22,907 24,447 20,425 18,470
Total Common Equity 0 110,221 111,310 11,522 11,338
Shares Outstanding 1,809.60 1,809.60 1,809.60 1,809.60 1,809.60
Book Value Per Share 0.00 60.91 61.51 6.37 6.27